Mammalian Polyclonal IgG Antibody Market

Market Overview:

The global mammalian polyclonal IgG antibody market size reached USD 1,092.2 Million in 2023. Looking forward, IMARC Group expects the market to reach USD 1,648.4 Million by 2032, exhibiting a growth rate (CAGR) of 4.54% during 2024-2032. The market growth is driven by the increasing collaborations between research institutes and industry players, the rising focus on monoclonal and polyclonal antibody research, the expanding global healthcare infrastructure, the growing use in autoimmune disease treatment, the escalating adoption of recombinant antibodies, and significant growth of the contract research organization (CRO) industry.

Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations. Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.

Mammalian Polyclonal IgG Antibody Market Trends:

Increasing prevalence of chronic diseases

The increasing number of cases of chronic diseases, such as cancer, cardiovascular disease, and autoimmune diseases, is a major factor leading to the expansion of the mammalian polyclonal IgG antibody market size. For instance, the prevalence of individuals aged 25 and older with at least one chronic disease, based on 28 recorded diagnoses in general practice, rose from 34.9% in 2004 to 41.8% in 2011, reflecting a statistically significant increase of 6.9 percentage points during that period. As these conditions require more sophisticated diagnostics and management, mammalian polyclonal IgG antibodies are commonly used in immunoassays, directed therapy, and modulation of the immune system. Due to the persistent growth in chronic medical conditions, the prevalent need for relative antibody-based and other solutions contributes to the further advancement of the market.

Rising demand for therapeutic antibodies

The rising demand for therapeutic antibodies is a key factor augmenting the mammalian polyclonal IgG antibody market share. Therapeutic antibodies are increasingly used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, due to their high specificity and ability to target disease-causing agents effectively. As biopharmaceutical companies develop more antibody-based therapies, the demand for polyclonal IgG antibodies, which are essential in immune response modulation and research applications, is growing. Additionally, advancements in antibody engineering and an increased focus on personalized medicine further enhance the adoption of therapeutic antibodies. This rising demand fuels research, development, and production of mammalian polyclonal IgG antibodies, contributing to significant market growth and expanding their applications in modern healthcare.

Significant growth in the biotechnology and pharmaceutical industries

The growth of the biotechnology and pharmaceutical industries is a significant driver of the market. As these industries expand, there has been increasing investments in research and development (R&D) activities involving innovative therapeutic and diagnostic solutions. Polyclonal IgG antibodies play a critical role in drug discovery, disease diagnostics, and therapeutic development, especially for complex diseases like cancer and autoimmune disorders. Continual advancements in biopharmaceutical technologies, such as antibody engineering, and the push for biologics and biosimilars are also driving the demand for these antibodies, leading to increased production and wider applications for these antibodies. Additionally, the industry's focus on personalized medicine and precision therapies increases the need for high-quality antibodies, further providing a boost to the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, product, application, and end use.

Breakup by Type:

• Goat
• Rabbit
• Horse
• Mouse
• Others
   

Breakup by Product:

• Cardiac Markers
• Metabolic Markers
• Renal Markers
• Others
   

Breakup by Application:

• ELISA
• Immunoturbidimetry
• Immunoelectrophoresis
• Antibody Identification
• Immunohistochemistry
• Immunocytochemistry
• Western Blotting
   

Breakup by End Use:

• Hospitals
• Diagnostic Centers
• Academic and Research Institutes
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global mammalian polyclonal IgG antibody market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• Abbiotec Inc.
• Abcam plc
• Bio-Rad Laboratories Inc.
• Cell Signaling Technology Inc.
• Creative Diagnostics
• Elabscience Biotechnology Inc.
• Geno Technology Inc.
• Merck KGaA
• Proteintech Group Inc.
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc.
   

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Mammalian Polyclonal IgG Antibody Market News:

• July 29, 2024: Bio-Rad Laboratories, Inc. announced the expansion of its Pioneer Antibody Discovery Platform. This enhancement includes the rapid generation and screening of bispecific antibodies, utilizing the company’s proprietary SpyLock Technology. This development is expected to boost the market growth by meeting the increasing demand for cutting-edge antibody therapeutics and diagnostic tools.

Report Coverage:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the mammalian polyclonal IgG antibody market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global mammalian polyclonal IgG antibody market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the mammalian polyclonal IgG antibody industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.